Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib Bioequivalence and Food/PPI Effect Study
NCT03130556Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glasdegib in acute myeloid leukemia (AML) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 5 days and Area Under the Curve From Time Zero to Last Measured Time Point at 5 days. Started May 2017; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03130556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130556.